176 related articles for article (PubMed ID: 11752202)
1. Molecular docking of competitive phosphodiesterase inhibitors.
Dym O; Xenarios I; Ke H; Colicelli J
Mol Pharmacol; 2002 Jan; 61(1):20-5. PubMed ID: 11752202
[TBL] [Abstract][Full Text] [Related]
2. Identification of inhibitor binding sites of the cAMP-specific phosphodiesterase 4.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Apr; 13(4):287-97. PubMed ID: 11306246
[TBL] [Abstract][Full Text] [Related]
3. Identification of substrate specificity determinants in human cAMP-specific phosphodiesterase 4A by single-point mutagenesis.
Richter W; Unciuleac L; Hermsdorf T; Kronbach T; Dettmer D
Cell Signal; 2001 Mar; 13(3):159-67. PubMed ID: 11282454
[TBL] [Abstract][Full Text] [Related]
4. Occupancy of the catalytic site of the PDE4A4 cyclic AMP phosphodiesterase by rolipram triggers the dynamic redistribution of this specific isoform in living cells through a cyclic AMP independent process.
Terry R; Cheung YF; Praestegaard M; Baillie GS; Huston E; Gall I; Adams DR; Houslay MD
Cell Signal; 2003 Oct; 15(10):955-71. PubMed ID: 12873709
[TBL] [Abstract][Full Text] [Related]
5. Dissecting the cofactor-dependent and independent bindings of PDE4 inhibitors.
Liu S; Laliberté F; Bobechko B; Bartlett A; Lario P; Gorseth E; Van Hamme J; Gresser MJ; Huang Z
Biochemistry; 2001 Aug; 40(34):10179-86. PubMed ID: 11513595
[TBL] [Abstract][Full Text] [Related]
6. Characterization of phosphodiesterase 4 in guinea-pig macrophages: multiple activities, association states and sensitivity to selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Br J Pharmacol; 1998 May; 124(1):129-40. PubMed ID: 9630352
[TBL] [Abstract][Full Text] [Related]
7. Identification of inhibitor specificity determinants in a mammalian phosphodiesterase.
Atienza JM; Susanto D; Huang C; McCarty AS; Colicelli J
J Biol Chem; 1999 Feb; 274(8):4839-47. PubMed ID: 9988724
[TBL] [Abstract][Full Text] [Related]
8. In vivo selective binding of (R)-[11C]rolipram to phosphodiesterase-4 provides the basis for studying intracellular cAMP signaling in the myocardium and other peripheral tissues.
Kenk M; Greene M; Thackeray J; deKemp RA; Lortie M; Thorn S; Beanlands RS; DaSilva JN
Nucl Med Biol; 2007 Jan; 34(1):71-7. PubMed ID: 17210463
[TBL] [Abstract][Full Text] [Related]
9. Regulation of cyclic AMP in rat pulmonary microvascular endothelial cells by rolipram-sensitive cyclic AMP phosphodiesterase (PDE4).
Thompson WJ; Ashikaga T; Kelly JJ; Liu L; Zhu B; Vemavarapu L; Strada SJ
Biochem Pharmacol; 2002 Feb; 63(4):797-807. PubMed ID: 11992650
[TBL] [Abstract][Full Text] [Related]
10. Activation and induction of cyclic AMP phosphodiesterase (PDE4) in rat pulmonary microvascular endothelial cells.
Zhu B; Kelly J; Vemavarapu L; Thompson WJ; Strada SJ
Biochem Pharmacol; 2004 Aug; 68(3):479-91. PubMed ID: 15242814
[TBL] [Abstract][Full Text] [Related]
11. Behavioural effects of selective PDE4 inhibitors in relation to inhibition of catalytic activity and competition for [3H]rolipram binding.
Kapui Z; Bence J; Boronkay E; Mikus E; Urbán Szabó K; Baranyi A; Arányi P
Neurobiology (Bp); 1999; 7(1):71-3. PubMed ID: 10746252
[No Abstract] [Full Text] [Related]
12. The oligomerization state determines regulatory properties and inhibitor sensitivity of type 4 cAMP-specific phosphodiesterases.
Richter W; Conti M
J Biol Chem; 2004 Jul; 279(29):30338-48. PubMed ID: 15131123
[TBL] [Abstract][Full Text] [Related]
13. Phosphodiesterase 4 in macrophages: relationship between cAMP accumulation, suppression of cAMP hydrolysis and inhibition of [3H]R-(-)-rolipram binding by selective inhibitors.
Kelly JJ; Barnes PJ; Giembycz MA
Biochem J; 1996 Sep; 318 ( Pt 2)(Pt 2):425-36. PubMed ID: 8809029
[TBL] [Abstract][Full Text] [Related]
14. Airway relaxant and anti-inflammatory properties of a PDE4 inhibitor with low affinity for the high-affinity rolipram binding site.
Martin C; Göggel R; Dal Piaz V; Vergelli C; Giovannoni P; Ernst M; Uhlig S
Naunyn Schmiedebergs Arch Pharmacol; 2002 Apr; 365(4):284-9. PubMed ID: 11919652
[TBL] [Abstract][Full Text] [Related]
15. Pregnancy induces a modulation of the cAMP phosphodiesterase 4-conformers ratio in human myometrium: consequences for the utero-relaxant effect of PDE4-selective inhibitors.
Méhats C; Tanguy G; Paris B; Robert B; Pernin N; Ferré F; Leroy MJ
J Pharmacol Exp Ther; 2000 Feb; 292(2):817-23. PubMed ID: 10640323
[TBL] [Abstract][Full Text] [Related]
16. cAMP-specific phosphodiesterase HSPDE4D3 mutants which mimic activation and changes in rolipram inhibition triggered by protein kinase A phosphorylation of Ser-54: generation of a molecular model.
Hoffmann R; Wilkinson IR; McCallum JF; Engels P; Houslay MD
Biochem J; 1998 Jul; 333 ( Pt 1)(Pt 1):139-49. PubMed ID: 9639573
[TBL] [Abstract][Full Text] [Related]
17. Implications of PDE4 structure on inhibitor selectivity across PDE families.
Ke H
Int J Impot Res; 2004 Jun; 16 Suppl 1():S24-7. PubMed ID: 15224132
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of PDE3B augments PDE4 inhibitor-induced apoptosis in a subset of patients with chronic lymphocytic leukemia.
Moon E; Lee R; Near R; Weintraub L; Wolda S; Lerner A
Clin Cancer Res; 2002 Feb; 8(2):589-95. PubMed ID: 11839681
[TBL] [Abstract][Full Text] [Related]
19. Analysis of a mutation in phosphodiesterase type 4 that alters both inhibitor activity and nucleotide selectivity.
Herman SB; Juilfs DM; Fauman EB; Juneau P; Menetski JP
Mol Pharmacol; 2000 May; 57(5):991-9. PubMed ID: 10779384
[TBL] [Abstract][Full Text] [Related]
20. The effects of both noradrenaline and CGP12177, mediated through human beta1 -adrenoceptors, are reduced by PDE3 in human atrium but PDE4 in CHO cells.
Kaumann A; Semmler AB; Molenaar P
Naunyn Schmiedebergs Arch Pharmacol; 2007 Apr; 375(2):123-31. PubMed ID: 17318500
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
